CONFIDENTIAL TREATMENT REQUESTED Third Amendment to the Research and Development Collaboration and License Agreement
Third Amendment to the
Research and Development Collaboration and License Agreement
This is the third Amendment (hereinafter “Third Amendment”) to the Research and Development Collaboration and License Agreement between Bayer Pharma AG, a company formed under the
laws of Germany, having a place of business at Xxxxxxxxxxxxxx 000, 00000 Xxxxxx, Xxxxxxx (hereinafter: “BAYER”) and Compugen Ltd, a company formed under the laws of Israel, having a place of business at 00 Xxxxxxxx Xxxxxx, Xxxxx 0000000, Xxxxxx
(hereinafter: “Compugen”) effective as of 5 August 2013, as amended on February 5, 2014 and on July 27, 2015 (hereinafter: the “Agreement”).
WHEREAS, the Parties wish to amend Exhibit 1.3 specifying the Bayer Development Process; and
WHEREAS, the Parties wish to amend the Agreement to revise certain milestone [***] as a result of the amended Exhibit 1.3, all in accordance with the terms and conditions of this
Third Amendment.
NOW THEREFORE IT IS AGREED AS FOLLOWS:
| 1. | The Parties agree to replace Exhibit 1.3 of the Agreement by Exhibit 1.3 attached to this Third Amendment, describing the “Bayer Development Process”. |
| 2. | The following language shall be added to the end of Section 0.0.0.0: |
“, except that solely with respect to [***] such milestone payment shall be [***] US Dollars ($[***]);”
| 3. | The following language shall be added to the end of Section 0.0.0.0: |
‘”, except that solely with respect to [***] such milestone payment shall be [***] US Dollars ($[***]);”
| 4. | This Third Amendment shall become effective on the date this Agreement is signed by the last of the Parties to sign it. |
| 5. | All capitalized terms used herein shall have the meaning set forth in the Agreement. Except as expressly amended pursuant to this Third Amendment, all other terms and conditions of the Agreement shall remain in force unchanged and apply to this Third Amendment. |
Certain information in this document, marked by [***], has been omitted pursuant to Item 601(b)(10)(iv) of
Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
|
SIGNED for and on behalf of
Bayer Pharma AG
|
SIGNED for and on behalf of
|
|
Date: April 17, 2016
|
Date: April 17, 2016
|
|
/s/ Xx. Xxxx Xxxxxxxxxxx
Xx. Xxxx Xxxxxxxxxxx
(Head Therapeutic Research Groups)
|
/s/ Xxxx Xxxxx-Xxxxx
Dr. Xxxx Xxxxx-Xxxxx
(President & CEO)
|
|
/s/ Xx. Xxxxxxx Xxxxx
Xx. Xxxxxxx Xxxxx
(Head Oncology III)
|
Certain information in this document, marked by [***], has been omitted pursuant to Item 601(b)(10)(iv) of
Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
2
Exhibit 1.3: Bayer Development Process
[***, 3 pages]
Certain information in this document, marked by [***], has been omitted pursuant to Item 601(b)(10)(iv) of
Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
3
